Morgan Stanley
CTOR icon

Morgan Stanley’s Citius Oncology CTOR Stock Holding History

Morgan Stanley’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15 Buy
+23
New +$18 ﹤0.01% 8318
2025
Q4 		– Sell
-5
Closed -$10 – 8524
2025
Q3 		$10 Buy
+5
New +$11 ﹤0.01% 8100

Other funds holding CTOR

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley's CTOR Position: Q2 2026 in Review

Morgan Stanley opened a new position in Citius Oncology (CTOR) in Q2 2026: 23 shares worth $15. The stake represents ﹤0.01% of the portfolio and ranks #8318 among its holdings. This is a return to the name: Morgan Stanley previously reported a position in CTOR as recently as Q3 2025.

Morgan Stanley first reported a position in CTOR in Q3 2025 and has held it in 2 quarters since. 19 funds tracked by Wall St. Rank hold CTOR as of Q2 2026.

  • Morgan Stanley held 23 shares of Citius Oncology worth $15 as of Q2 2026.
  • Citius Oncology was a new Morgan Stanley position in Q2 2026.
  • Citius Oncology made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #8318 holding.
  • Morgan Stanley first reported a position in Citius Oncology in Q3 2025 and has held it in 2 quarters since.
  • 19 funds tracked by Wall St. Rank held Citius Oncology as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.